The urinary tract conditions of patients with Escherichia coli infection improve fosfomycin activity.

The steps by which E. coli strains harboring mutations related to fosfomycin resistance arise and spread during urinary tract infections (UTIs) are far from being understood. A study performed by several REIPI groups (Hospital Universitario Virgen del Rocío, Hospital Universitario Virgen Macarena and Centro Nacional de Biotecnología) evaluates the effects of the urinary tract conditions…

Details

First insights into the role of vrf, a newly characterized gene of Salmonella Typhimurium

Salmonella Typhimurium is an important pathogen responsible for causing food-borne disease. This bacterium carries conserved virulence factors involved in the process of infection, allowing survival, replication and invasion inside the host cell in order to cause the disease. In this study, researchers from Dr. Jordi Vila’s group at the Barcelona Institute for Global Health (ISGlobal)-…

Details

Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial. Lancet Haematol 2017

The optimal duration of empirical antibacterial therapy for febrile neutropenia without microbiological diagnosis in haematological patients is not well defined; the classical approach of continuing antimicrobial therapy until neutrophil recovery may prolong it unnecessarily. This study aimed to establish whether the discontinuation of antimicrobial therapy driven by a clinical approach regardless of neutrophil recovery would…

Details

The prevalence and transmission dynamics of Escherichia coli ST131 among contacts of infected community and hospitalized patients

This study is the first assessment of longitudinal persistence of Escherichia coli ST131, including both ESBL and non-ESBL-producing isolates. This clone is considered the most important in the increased prevalence of quinolones resistant isolates and one of those responsible for the worldwide dissemination of the blaCTX-M-15 gene. Our results showed a rapid dynamic of ST131…

Details

Optimisation of empirical antimicrobial therapy in patients with haematological malignancies and febrile neutropenia (How Long study): an open-label, randomised, controlled phase 4 trial

How Long? the just Continuation of empirical antimicrobial therapy (EAT) for febrile neutropenia in patients with haematological malignancies until neutrophil recovery could prolong the therapy innecessarily. We did an investigator-driven, superiority, open-label, randomised, controlled phase 4 clinical trial in six hospitals in Spain. For the experimental group, EAT was withdrawn after 72 h or more…

Details

Genomics of Extensively Drug-Resistant (XDR) Pseudomonas aeruginosa

REIPI researchers coordinated by the Hospital Son Espases Group have analyzed the molecular epidemiology and the whole genome sequencing resistome of a large collection of XDR P. aeruginosa strains isolated from Spanish hospitals. The main conclusions of the study are as follows: (1) Most strains were resistant to all antipseudomonal agents except colistin, amikacin and…

Details

High Resolution Melting Assay to detect azole resistance in Aspergillus fumigatus

The global emergence of azole resistant Aspergillus fumigatus strains is a growing public health concern. Different patterns of azole resistance are linked to mutations in cyp51A. The Mycology Reference Laboratory of the National Centre for Microbiology has developed and validated a new screening sequencing-free molecular method based in a High Resolution Melting (HRM) assay to…

Details

Empiric Therapy with Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β-Lactamase–Producing Enterobacteriaceae: Results from the INCREMENT Cohort.

This study, in advance access published in Clinical Infectious Diseases in August 2017, was coordinated at University Hospital Virgen Macarena with the collaboration of a large number of hospitals belonging to the REIPI/ESGBIS/INCREMENT group included in the REIPI network. The most relevant results, described below, can have a significant impact in the treatment and outcome…

Details